Ovid Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated June 5, 2020, discloses the results of the Annual Meeting of Stockholders held on June 4, 2020. Ovid Therapeutics Inc. is a Delaware corporation with its principal executive offices in New York, New York, and its common stock trades on The Nasdaq Stock Market LLC under the symbol "OVID".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting:
- Proposal 1 (Election of Directors): Stockholders elected the nominees to serve three-year terms. The voting results were as follows:
- Dr. Jeremy M. Levin: 29,112,192 votes For; 3,061,957 votes Withheld; 13,606,639 Broker Non-Votes.
- Dr. Karen Bernstein: 29,100,762 votes For; 3,073,387 votes Withheld; 13,606,639 Broker Non-Votes.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020. The voting results were:
- For: 45,725,464
- Against: 13,316
- Abstain: 42,008
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves solely to report the outcome of the shareholder vote.
Key Facts for Investor Verification
- Confirmation that Dr. Jeremy M. Levin and Dr. Karen Bernstein were successfully elected to the Board of Directors.
- Verification that KPMG LLP was ratified as the independent auditor for the 2020 fiscal year.
- Review of the definitive proxy statement filed on April 24, 2020, for detailed background on the proposals and director nominees.